Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T18:22:41.725Z.
Calculation as of: 2026-10-06T18:22:41.725Z.
Quote observation: 2026-10-06T18:20:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4941427db71110f151888ce76d054bb3757469c79637f9c20e96b8da83d8f989
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Rocket Pharmaceuticals, Inc.
Market Cap
$271.89M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$271.06M
EBITDA Yield
N/A
TTM Avg
1.92%
3Y Avg
1.92%
5Y Avg
1.92%
Market Cap
$270.20M
EBITDA Yield
N/A
TTM Avg
0.12%
3Y Avg
0.12%
5Y Avg
0.12%
Market Cap
$270.31M
EBITDA Yield
N/A
TTM Avg
53.15%
3Y Avg
20.52%
5Y Avg
13.83%
Market Cap
$269.70M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$264.94M
EBITDA Yield
N/A
TTM Avg
10.04%
3Y Avg
10.04%
5Y Avg
9.67%
Market Cap
$264.63M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rocket Pharmaceuticals, Inc. (RCKT) | $271.89M | N/A | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $271.00M | N/A | N/A | N/A | N/A |
| SAB Biotherapeutics, Inc. (SABS)vs › | $271.06M | N/A | 1.92% | 1.92% | 1.92% |
| Treace Medical Concepts, Inc. (TMCI)vs › | $270.20M | N/A | 0.12% | 0.12% | 0.12% |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $270.31M | N/A | 53.15% | 20.52% | 13.83% |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $269.70M | N/A | N/A | N/A | N/A |
| Scribe Therapeutics Inc. (SCTX)vs › | $272.46M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $264.94M | N/A | 10.04% | 10.04% | 9.67% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.63M | N/A | N/A | N/A | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $261.97M | N/A | 55.26% | 33.09% | 19.40% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
